Pharmaceutical News

RSS

Conn. AG launches probe of CVS prescription plan termination threat

Richard Blumenthal, the Connecticut attorney general and a candidate for the U.S. Senate, announced an investigation of CVS Caremark after the corporation threatened to terminate a discount prescription drug program, Dow Jones Newswires/The Wall Street Journal reports.

25 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Emergent BioSolutions Inc. announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company's international sales efforts have resulted in these sales of an undisclosed number of BioThrax doses for aggregate revenue of approximately $2.3 million in the second quarter.

24 Jun 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

FDA grants t2cure orphan drug designation for t2c001 in Buerger's Disease

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's Disease. The Company also announced that in a concurrent application in Europe the EMA's Committee for Orphan Medicinal Products recently recommended t2c001 for orphan designation to the European Commission.

24 Jun 2010

AVEO receives EMA orphan medicinal product designation for tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency (EMA).

24 Jun 2010

Increased drug development cost drives pharma companies to seek better opportunities in emerging markets

The increased cost of drug development has impelled pharmaceutical companies to seek better opportunities in emerging markets to successfully expand and sell their products. Most pharmaceutical companies consider emerging markets lucrative due to their economical infrastructure and manpower costs and a significant untapped market potential with a large population.

24 Jun 2010

VISINE launches new Maximum Redness Relief Formula

Now irritated, red eyes can get the fast, effective relief they need with the launch of NEW VISINE® Maximum Redness Relief Formula. Plus, the free new VISINE® Red Eye Remover Application lets iPhone® and iPod® Touch users eliminate red eye from their photos in moments.

24 Jun 2010

Extract of French maritime pine tree bark reduces hay fever symptoms

An estimated 60 million people in the U.S. are affected by allergic rhinitis, commonly known as hay fever, according to the American Academy of Allergy Asthma and Immunology. Hay fever is an allergic inflammation of the nasal airways that causes itching, swelling, mucus production, hives and rashes. A study published in the June 14, 2010 issue of Phytotherapy Research demonstrates Pycnogenol- (pic-noj-en-all), an antioxidant plant extract derived from the bark of the French maritime pine tree, substantially improves the symptoms of hay fever.

24 Jun 2010

Carvedilol drug may lessen degenerative impact of Alzheimer's disease: Researchers

Researchers at Mount Sinai School of Medicine have found that the drug carvedilol, currently prescribed for the treatment of hypertension, may lessen the degenerative impact of Alzheimer's disease and promote healthy memory functions. The new findings are published in two studies in the current issues of Neurobiology of Aging and the Journal of Alzheimer's Disease.

24 Jun 2010

FDA cancels Advisory Committee review of Lux Biosciences' voclosporin NDA

Isotechnika Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Dermatology and Ophthalmology Drugs Advisory Committee review of partner, Lux Biosciences', New Drug Application (NDA) for voclosporin on June 28, 2010.

24 Jun 2010

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Merck (Merck is known as MSD outside the United States and Canada) today announced a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute a number of established MSD products in South Africa. The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter (OTC) products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.

24 Jun 2010

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.

24 Jun 2010

Treatment options for patients with MS

The best one-word description for multiple sclerosis is "unpredictable," according to the June issue of Mayo Clinic Women's HealthSource. MS interferes with the communication between the brain and the rest of the body. Just how that interference plays out in symptoms is different for everyone -- thus, the unpredictable label.

24 Jun 2010

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Watson Pharmaceuticals, Inc. announced that its subsidiary, Watson Laboratories, Inc. has received tentative approval today from the United States (U.S.) Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Fentanyl Citrate Buccal tablets, 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg.

24 Jun 2010

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

Valeant Pharmaceuticals International today announced that Oxsoralen-Ultra, its therapy for severe psoriasis, is now available again in the United States on a limited supply basis.

23 Jun 2010

EUCODIS Bioscience launches high-performance beta-lactamase

EUCODIS Bioscience, a developer and manufacturer of customized enzymes today announced that it has launched a high-performance beta-lactamase designed to inactivate a broad range of beta-lactam antibiotics. EUCODIS Bioscience is marketing the product under the LacBuster(TM) brand.

23 Jun 2010

US physicians concerned about health risk to patients from heat-damaged medicinal products

In a recent Harris Interactive survey of US physicians about the proper storage and handling of temperature-sensitive medicines prescribed and administered to patients, physicians reported being concerned about this issue, and the overwhelming majority are concerned that heat-damaged products resulting from cumulative exposure to temperatures outside the specified temperature range pose a health risk to patients. The announcement of the study findings was made today by Temptime Corporation.

23 Jun 2010

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Patients who had experienced a heart attack and lowered their blood homocysteine levels with folic acid and vitamin B12 supplementation did not have an associated lower risk of heart attack, coronary death or stroke, according to a study in the June 23/30 issue of JAMA. However, the researchers did find that folic acid supplementation did not increase the risk of cancer, which has been speculated.

23 Jun 2010

Global weight management ingredients market to reach $13.9 million by 2015

Obesity rates, which have been steadily rising in Europe and the United States, are now increasing in Asian nations as well. While healthy eating and lifestyle management are the key solutions to weight management, they remain challenging for many consumers. As a result, the weight management ingredients market offers significant prospects worldwide.

23 Jun 2010

Pharmaceutical News

Conn. AG launches probe of CVS prescription plan termination threat

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

Emergent BioSolutions completes sales, deliveries of BioThrax to allied international governments

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

FDA grants t2cure orphan drug designation for t2c001 in Buerger's Disease

AVEO receives EMA orphan medicinal product designation for tivozanib

Increased drug development cost drives pharma companies to seek better opportunities in emerging markets

VISINE launches new Maximum Redness Relief Formula

Extract of French maritime pine tree bark reduces hay fever symptoms

Carvedilol drug may lessen degenerative impact of Alzheimer's disease: Researchers

FDA cancels Advisory Committee review of Lux Biosciences' voclosporin NDA

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Treatment options for patients with MS

Watson's ANDA for Fentanyl Citrate Buccal tablets receives tentative FDA approval

Oxsoralen-Ultra therapy for severe psoriasis now available in the U.S. on a limited supply basis

EUCODIS Bioscience launches high-performance beta-lactamase

US physicians concerned about health risk to patients from heat-damaged medicinal products

Folic acid and vitamin B12 lower homocysteine levels in patients who experience heart attack: JAMA

Global weight management ingredients market to reach $13.9 million by 2015

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News